CD274 and triple-negative breast carcinoma: This was an adaptive, non-comparative phase 2 trial involving patients (n = 66) with metastatic triple-negative breast cancer, a type of malignancy which is poorly responsive to PD-1/PD-L1-targeted immunotherapy.